FBR


This Analyst Sidelined on House of Mouse Walt Disney Co (DIS) Despite Growth in Domestic Margins

FBR analyst Barton Crockett came out with a research note on shares of Walt Disney Co (NYSE:DIS), after the House of Mouse posted results for …

FBR Weighs in on LendingClub Corp (LC) in Wake of Weak 2Q:16

On Monday, LendingClub Corp (NYSE:LC) released second-quarter results after facing millions of dollars in higher costs, elevated professional fees, investor incentives, and severance …

FBR Chimes in on Genocea Biosciences Inc (GNCA) Following 2Q16 Update

Genocea Biosciences Inc (NASDAQ:GNCA) just hosted a conference call to discuss its second-quarter results and to highlight its clinical pipeline progress. The biotech firm continues to commercialize …

FBR Remains Neutral on Hecla Mining Company (HL) Despite 2Q Beat

In a research note issued Friday, FBR analyst Lucas Pipes reiterated a Market Perform rating on shares of Hecla Mining Company (NYSE:HL), with a …

FBR Analyst Chimes In On Synthetic Biologics Inc (SYN) Following Positive Phase II FDA Meeting

On Tuesday morning, Synthetic Biologics Inc (NYSEMKT:SYN) made a positive stride with the completion of an End of Phase 2 meeting with the FDA for …

FBR Remains Sidelined on Freeport-McMoRan Inc (FCX)

In a research report released today, FBR analyst Lucas Pipes reiterated a Market Perform rating on shares of Freeport-McMoRan Inc (NYSE:FCX) with a price …

FBR Upgrades Ballard Power Systems Inc. (USA) (BLDP); Sees 44% Upside for the Stock

In a research report issued Tuesday, FBR analyst Carter Driscoll upgraded shares of Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) to an Outperform (from Market Perform), …

FBR Analyst Weighs In on Anavex Life Sciences Corp. (AVXL) Following Efficacy Data in AD

In a research report released Tuesday, FBR analyst Christopher James reiterated an Outperform rating on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), with a $10 price …

FBR Analyst Raises Price Target for Sprint Corp (S); Notes Standout First Quarter Results

FBR analyst David Dixon weighs in on Sprint Corp (NYSE:S) following turnaround momentum with what Dixon considers “standout” 1Q:16 results. Earnings of $2.

FBR Analyst Comments on Keryx Biopharmaceuticals (KERX) Ahead of 2Q:16 Earnings Results

After an encouraging update from Keryx Biopharmaceuticals (NASDAQ:KERX) management about approved drug Auryxia, a phosphate binder designed to treat iron deficiency anemia (IDA) …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts